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19045), and patients who underwent PCI with BMS (group 2; N12559) and DES (group
3; N19346) between January 2003- December 31 2004 (DES era). All cause and
cardiovascular mortality was followed for all groups for 5 years.
Results: At 5 year follow up the unadjusted all- cause mortality was significantly higher
in group 2 (18.41%; p0.003) when compared with group 1 (14.01%) and group 3
(13.27%). The unadjusted cardiovascular mortality was significantly lower in group 3
(5.68% vs. 7.66% in gr 1 and 9.01% in gr 2; p0.0001). After adjusting for baseline
characteristics such as age, sex, race, diabetes, hypertension, renal disease, anemia, cancer,
cerebrovascular disease and left ventricular dysfunction there was a survival benefit
associated with DES ; the hazard ratios for total mortality and cardiovascular mortality
were 0.74 (95% CI 0.70 to 0.78; p0.0001) and 0.58 (95% CI 0.53 to 0.63; p0.0001)
respectively. For the patients from group 3 there was a significant survival benefit for
cardiovascular mortality (HR 0.83; CI 0.77-0.90; p0.0001) but not for total mortality
(HR 0.96; CI 0.91-1.02; p0.16) after adjustment for baseline characteristics.
Conclusions: In contemporary practice there appears to be a baseline selection bias in the
choice of stent type used during a PCI, with BMS being preferentially used in sicker
patients. This translates in a survival benefit in patients receiving DES, which may explain
the discrepancies in survival between stent registries and RCT.
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Background: It is now common practice to use coronary stents following PTCA to
restore blood flow in patients with CAD. The purpose of this study is to evaluate the
utilization of bare-metal stents (BMS) and drug-eluting stents (DES) and their revascu-
larization and mortality rates in the U.S. from 1997-2009.
Methods: The Medicare 5% LDS analytical files were queried to identify patients with
BMS and DES between 1997-2009 using ICD-9-CM. The subsequent rates of revascu-
larization and mortality were evaluated.
Results: A total of 88,000 BMS procedures were identified between 1997-2009 with a
revascularization rate of 31%. In addition, 68,300 DES procedures were identified from
2002-2009 with an overall revascularization rate of 19%. Within 2 years of FDA
approval, the DES dominated the stent market, accounting for 88.4% of all coronary stent
procedures in 2005. Due to DES safety concerns of late stent thrombosis, BMS utilization
increased steadily to 37% in 2007 with a simultaneous decrease in DES usage.
revascularization burden increased considerably from 8.2% in 1997 to 44.2% in 2009 for
BMS. The revascularization burden for DES increased at the same rate from 2006-2009.
The majority of patients undergoing stenting procedures were also diagnosed with
hypertension (75-85%) with revascularization rates higher among this population than
primary procedures. Over 60% of patients undergoing a DES stenting procedure (primary
or revascularization) are implanted with one stent while 27% are implanted with two
stents and less than 10% receive 3 or more stents. The same trend was observed for
patients undergoing primary or revascularization BMS procedures. Ten-year Kaplan Meir
mortality rates were also assessed among the DES and BMS patient populations. The
average hospitalization charges for primary DES procedures was $64,000, whereas the
average charges for BMS procedures were $10,000-23,000 lower than DES procedures.
Conclusions: Temporal trends showed that concerns about late-stent thrombosis with use
of DES led to a sharp decline in utilization. Analysis of mortality and revascularization
following BMS and DES procedures provided information about the comparative safety
and effectiveness of these procedures.
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Background: Acute cerebrovascular episode (CVA) following percutaneous coronary
intervention (PCI) is a rare but devastating complication. We sought to determine the
incidence and predictors of stroke following PCI in United States.
Methods: The Nationwide Inpatient Sample (NIS) database was used to identify all
patients who developed acute CVA following PCI between January and December 2009.
Risk adjusted logistic regression was performed to identify independent predictors of
acute stroke following PCI.
Results: Of the 444,326 patients who underwent PCI, 437 (0.1%) acute strokes were
identified. The in-hospital mortality rate in patients who developed stroke was signifi-
cantly higher than in control group (2.3% vs. 0.6%, p  0.01). Independent predictors of
stroke following PCI were history of drug abuse (OR 7.2, 95% CI {4.5 – 11.4}, p0.01),
valvular heart disease (OR 3.2, 95% CI {1.6 – 6.7}, p  0.01), age 65 (OR 2.9, 95%
CI {2.3 – 3.7}, p0.01), diabetes with complications (OR 2.0, 95% CI {1.4 – 2.7}, p
0.01), female sex (OR 1.6, 95% CI {1.3 – 2.0}, p  0.01), history of coronary artery
bypass grafting (OR 1.6, 95% CI {1.2 – 2.1}, p  0.01) and history of myocardial
infarction (OR 1.5, 95% CI {1.2 – 1.9}, p  0.01).
Conclusions: In this observational study we found that risk of stroke following PCI is
low, whereas the in-hospital mortality associated with this complication is high. The
independent predictors of stroke complication include history of drug abuse, valvular
heart disease, advanced age, diabetes with complications, prior CABG or MI.
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Background: Endothelial dysfunction of coronary artery has been reported in patients
following the first generation drug eluting stent (DES) implantation. However, the
incidence and clinical relevance of the second generation DES-induced endothelial
dysfunction have not been fully investigated. The aim of this study was to estimate the
incidence and clinical relevance of endothelial dysfunction after implantation of
everolimus-eluting stent (EES).
Methods: Since June 2006 until August 2011, the present study enrolled 757 patients
who were treated solely with DES for de novo lesions, from our prospective institutional
database. The patients (279 patients with sirolimus-eluting stent (SES), 210 patients with
paclitaxel-eluting stent (PES), and 268 patients with EES) were requested to undergo
8-month follow-up angiography. Endothelial function was evaluated, in case the patients
had angina symptom and/or positive exercise electrocardiogram test without in-stent
restenosis at the time of follow-up angiography by infusion of incremental acetylcholine
and isosorbide dinitrate into the coronary artery. Vascular responses were quantitatively
measured in segments proximal, distal, proximal reference and distal reference to DES
location. Endothelial dysfunction was defined as abnormal vasoconstriction of  3%
mean vessel diameter changes.
Results: Follow-up angiography was performed in 624 patients (82.4%)of the 757
patients. There were 59 patients (7.8%) who met the inclusion criteria for endothelial
function test, 25 patients (8.9%) with SES, 15 patients (7.1%) with PES, 19 patients
(7.1%) with EES. In all the 3 groups significant vasoconstriction after acetylcholine
infusion was observed in segments distal to stents compared to baseline(p0.05).
Vasodilation in response to isosorbide dinitrate infusion was also observed. Endothelial
dysfunction was quantitatively assessed in all the 59 patients at distal segments to DES.
No significant differences were observed in percent diameter changes from baseline
among the groups.
Conclusions: Clinically relevant endothelial dysfunction following EES implantation
seems to be present in approximately 7%, which is similar to the first generation DES
implantation.
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Background: The level of appropriateness of PCI in the appropriate use criteria (AUC)
are based on degree of symptoms and abnormalities on stress testing. Using these criteria,
PCI in patients with asymptomatic CAD (ACAD) is often labeled as inappropriate.
However, whether this is due to increased harm or perceived decreased benefit, is not
clear. Furthermore, many PCI’s performed for other instances not related to angina (i.e.
CHF, arrhythmias) and are not included as reasons for PCI in the AUC. Therefore, we
sought to investigate the outcomes of patients undergoing PCI for asymptomatic CAD
compared to those with stable angina (SA).
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Methods: We examined all patients In the NHLBI Dynamic Registry presenting with
ACAD and SA to understand difference in clinical characteristics and 1-year adverse
events.
Results: Of all patients in the NHLBI Dynamic Registry, 2174 underwent PCI for SA,
and 742 for ACAD. Patients receiving revascularization for ACAD compared to SA were
more likely to have a history of congestive heart failure (14% vs 9%, p0.0001) and HTN
(75% vs 71%, p0.05). In addition, Patients with ACAD had an increased prevalence of
non-cardiac comorbidites compared to SA patients (43% vs 31%, p0.0001) which
included a significant increase in renal disease (10% vs 6% p0.001), peripheral vascular
disease (10% vs 7%, p0.05), pulmonary disease (10% vs 6%, p0.01), and cancer (15%
vs 11%, p0.01). The prevalence of hyperlipidemia (72% vs 75%) and diabetes (33% vs
30%) were similar in both groups. There were no differences between the extent of
coronary artery disease or prior myocardial infarction in patient revascularized for ACAD
and SA. The combined adjusted 1-year mortality and reinfaction incidence (hazard ratio
0.95; 95% CI; 0.69-1.3) were similar between ACAD and SA patients.
Conclusions: Our analysis shows that patients with ACAD have similar 1-year outcomes
to SA patients after undergoing PCI while having increased co-morbid conditions. Given
these findings, further study is needed on the outcomes of patients with ACAD so that
they can be more appropriately represented in the AUC guidelines.
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Background: The utilization of the ’appropriate use criteria’ (AUC) has been contro-
versial and suggested inappropriate and uncertain PCIs may not be uncommon. The issues
raised are unlikely to be confined to the US. We therefore applied the AUC to patients
with stable angina undergoing PCI at our tertiary centre in order to gain a UK perspective.
Methods: We performed a restospective analysis of 200 consecutive patients with known
stable angina referred from the chest pain clinic for PCI. The appropriateness of PCI was
adjudicated using the published AUC and patients were grouped into those apparently
undergoing appropriate, inappropriate or uncertain PCI.We determined the proportion of
patients in the uncertain group who had either significant symptoms, intermediate risk or
optimal medical therapy (OMT) in order to determine those in whom PCI is known to be
beneficial and those where the evidence is less clear.
Results: One hundred and twenty nine (64.5%) of PCIs were classified as appropriate,
while 64 (32%) could be classified as uncertain indications and 7 (3.5%) were deemed
inappropriate (Table 1). Inappropriate procedures were more common in patients with
CCS I/II, those with low risk stress testing and in those not receiving OMT. Of the
uncertain PCIs, 55 (85.9%) patients had either CCS III/IV, intermediate risk stress tests or
were on OMT, with 9 (14.1%) having either CCS I/II, low risk stress tests or no OMT.
Variable
Appropriate
(n129)(%)
Uncertain
(n64)
(%)
Inappropriate
(n7) (%) p value
Angina 0.036
none 0 0 0
CCS I 13 (10.1) 11 (17.2) 0
CCS II 73 (56.6) 44 (68.8) 7 (100)
CCS III 36 (27.9) 8 (12.5) 0
CCS IV 7 (5.4) 1 (1.6) 0
Risk on noninvasive
testing
0.001
low 11 (8.5) 10 (15.6) 7 (100)
intermediate 65 (50.5) 40 (62.5) 0
high 39 (30.2) 0 0
not performed 14 (10.9) 14 (21.9) 0
Antianginals 0.027
optimal (2
drugs)
83 (64.3) 13 (20.3) 0
minimal/none
(2 drugs)
46 (35.7) 51 (79.7) 7 (100)
Coronary stenoses 0.027
1 67 (51.9) 40 (62.5) 5 (71.4)
2 37 (28.7) 22 (34.4) 2 (28.6)
3 25 (19.4) 2 (3.1) 0
Proximal LAD
stenosis
51 (39.5) 18 (28.1) 0 0.043
CCS III/IV or
intermediate risk
or OMT
– 55 (85.9) – –
CCS I/II or low risk
or no OMT
– 9 (14.1) – –
Conclusions: The majority of PCI for stable angina was appropriate, with only 3.5% of
procedures deemed inappropriate. Almost one third fall within the uncertain category
creating a clinical challenge. We have shown that the majority have either significant
symptoms, an intermediate risk on stress testing or are on optimal medication. Conse-
quently, many are likely to warrant and benefit from PCI and care must be taken not to
deny them this treatment for the fear of ’inappropriate’ criticism.
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Background: The aim of this study is to compare clinical outcomes for seven years,
between sirolimus-eluting stent (SES) and BMS.
Methods: During the BMS and drug-eluting stent (DES) transition period (from April
2002 to April 2004), 434 consecutive patients with 482 lesions underwent percutaneous
coronary intervention, using BMS or SES. Using propensity score mathing, 186 patients
with BMS and 166 patients with DES were selected. Seven year clinical outcomes of
major adverse cardiac events (MACE), such as cardiac death, myocardial infarction (MI)
and ischemia-driven target vessel revascularization (TVR), and angiographic definite stent
thrombosis (ST) were compared.
Results: At the clinical follow up for 1 year, patients with DES showed significantly
lower MACE (9.1% in BMS vs. 3.0% in DES, p0.024) than those with BMS. This
reduction was mainly driven by a decrease in TVR (8.1% vs. 2.4%, p0.024), although
there was no significant difference in MI or death. However, cumulative MACE for 7
years was similar (24.7% in BMS vs. 17.4% in DES, p0.155). There was no significant
difference in MI (4.3% in BMS vs. 3.0% in DES, p0.571), TVR (15.6% in BMS vs.
15.7% in DES, p0.862), death (9.1% in BMS vs. 5.4% in DES, p0.218) and ST (1.1%
in BMS vs. 1.8% in DES, p0.533).
Conclusions: The TVR were gradually increased from 1 to 7 years in DES, on the
contrary to that of BMS. Although DES showed better clinial outcomes in the early period
after implantation, it didn’t show significant benefits in the long-term follow up, compared
with that of BMS.
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